Amylyx Pharmaceuticals, Inc. filed a Form 8-K on August 18, 2026, disclosing that it hosted an investor and analyst conference call on that date to discuss positive topline results from the LUCIDITY Phase 3 clinical trial evaluating avexitide in participants with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery.

Key Highlights

  • Clinical trial results: Amylyx Pharmaceuticals reported positive topline results from the LUCIDITY Phase 3 clinical trial, according to the filing.
  • Drug and indication: The trial evaluated the efficacy and safety of avexitide in participants with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery.
  • Investor event: The company hosted a conference call with investors and analysts on August 18, 2026, to discuss the results.
  • Exhibit attached: Selected slides from the investor presentation used during the conference call are attached as Exhibit 99.1 to the filing.
  • Signed by: The filing was signed by James M. Frates, Chief Financial Officer of Amylyx Pharmaceuticals, Inc.

Amylyx Discloses Positive LUCIDITY Phase 3 Topline Results for Avexitide

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), headquartered at 55 Cambridge Parkway, Suite 6W, Cambridge, Massachusetts, filed a current report on August 18, 2026, under Item 8.01 (Other Events) of Form 8-K. According to the filing, the company hosted a conference call with investors and analysts on that same date to present what it described as "positive topline results" from its LUCIDITY Phase 3 clinical trial.

The filing states that the LUCIDITY trial evaluated the efficacy and safety of avexitide in participants with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery. The filing does not include specific numerical data from the trial results within the body of the 8-K itself; rather, the company noted that selected slides from the investor presentation used during the conference call are attached as Exhibit 99.1 and incorporated by reference into the report.

The 8-K was signed by James M. Frates in his capacity as Chief Financial Officer. The company's common stock, with a par value of $0.0001 per share, is listed on the Nasdaq Global Select Market under the trading symbol AMLX. Amylyx is incorporated in Delaware and holds Commission File Number 001-41199.

What Was Disclosed

Amylyx Pharmaceuticals disclosed via an August 18, 2026 current report that it held an investor conference call to discuss positive topline Phase 3 results for avexitide in post-bariatric hypoglycemia, with the presentation slides attached as Exhibit 99.1.